Opinion|Videos|September 30, 2024
ESMO 2024 Trial Updates: Contact-02
Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone metastases, providing crucial insights into treatment efficacy for these specific metastatic sites.
Advertisement
Advertisement
Related to this article
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
Advertisement
Advertisement
Trending on Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Late-Breaking Breast Cancer Data at ESMO 2026 Highlight ADCs and Ribociclib
3
Elranatamab Improves PFS in Relapsed/Refractory Multiple Myeloma
4
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
5